|
1) 堺 秀人, 黒川 清, 斉藤喬雄, 他. 難治性ネフローゼ症候群(成人例)の診療指針-平成13年度までの調査研究より-. 日腎会誌. 2002; 44: 751-61
|
|
|
|
2) Shiiki H, Saito T, Nishitani Y, et al. Prognosis and risk factors for idiopathic membranous nephropathy with nephrotic syndrome in Japan. Kidney Int. 2004; 65: 1400-7
|
|
|
|
|
3) 横山 仁, 浅香充宏, 山谷秀喜, 他. ネフローゼ症候群治療の進歩-成人領域. 日腎会誌. 2007; 49: 108-12
|
|
|
|
|
|
4) Ponticelli C, Zucchelli P, Passerini P, et al. A randomized trial of methylprednisolone and chlorambucil in idiopathic membranous nephropathy. N Engl J Med. 1989; 320: 8-13
|
|
|
|
|
|
5) Ponticelli C, Altieri P, Scolari F, et al. A randomized study comparing methylprednisolone plus chlorambucil versus methylprednisolone plus cyclophosphamide in idiopathic membranous nephropathy. J Am Soc Nephrol. 1998; 9: 444-50
|
|
|
|
|
|
6) Jha V, Ganguli A, Saha TK, et al. A randomized, controlled trial of steroids and cyclophosphamide in adults with nephrotic syndrome caused by idiopathic membranous nephropathy. J Am Soc Nephrol. 2007; 18: 1899-904
|
|
|
|
|
|
7) Cattran DC, Appel GB, Hebert LA, et al. A randomized trial of cyclosporine in patients with steroid-resistant focal segmental glomerulosclerosis. Kidney Int. 1999; 56: 2220-6
|
|
|
|
|
|
8) Nayagam LS, Ganguli A, Rathi M, et al. Mycophenolate mofetil or standard therapy for membranouos nephropathy and focal segmental glomerulosclerosis: a pilot study. Nephrol Dial Transplant. 2008; 23: 1926-30
|
|
|
|
|
|
9) Prytula A, Iijima K, Kamei K, et al. Rituximab in refractory nephrotic syndrome. Pediatr Nephrol. 2010; 25: 461-8
|
|
|
|
|
|
10) 斉藤喬雄, 岩野正之, 佐藤 博, 他. 難治性ネフローゼ症候群の治療に関する研究. In: 松尾清一主任研究者. 厚生労働科学研究費補助金難治性疾患克服研究事業 進行性腎障害に関する調査研究 平成21年度総括・分担研究報告書. 2010. p.99-109
|
|
|
|
|
|
11) Takeda A, Horike K, Onoda H, et al. Benefits of cyclosporine absorption profiling in nephrotic syndrome: preprandial once-daily administration of cyclosporine microemulsion improves slow absorption and can standardize the absorption profile. Nephrology. 2007; 12: 197-204
|
|
|
|
|
|
12) Shirai S, Yasuda T, Tsuchida H, et al. Preprandial microemulsion cyclosporine administration is effective for patients with refractory nephrotic syndrome. Clin Exp Nephrol. 2009; 13: 123-9
|
|
|
|
|
|
13) Shibasaki T, Koyama A, Hishida A, et al. A randomized open-label comparative study of conventional therapy versus mizoribine onlay therapy in patients with steroid-resistant nephrotic syndrome (postmarketing survey). Clin Exp Nephrol. 2004; 8: 117-26
|
|
|
|
|
|
14) Muso E, Mune M, Fujii Y, et al. Significantly rapid relief from steroid-resistant nephrotic syndrome by LDL apheresis compared with steroid monotherapy. Nephron. 2001; 89: 408-15
|
|
|
|
|
|
15) Muso E, Mune M, Yorioka N, et al. Beneficial effect of low-density lipoprotein apheresis (LDL-A) on refractory nephrotic syndrome (NS) due to focal glomerulosclerosis (FGS). Clin Nephrol. 2007; 67: 341-4
|
|
|
|
|
|
16) Kopp JB, Smith MW, Nelson GW, et al. MYH9 is a major-effect risk gene for focal segmental glomerulosclerosis. Nat Genet. 2008; 40: 1175-84
|
|
|
|
|
|
17) Brown EJ, Schlöndorff JS, Becker DJ, et al. Mutations in the formin gene INF2 cause focal segmental glomerulosclerosis. Nat Genet. 2010; 42: 72-6
|
|
|
|
|
|
18) Faul C, Donnelly M, Merscher-Gomez S, et al. The actin cytoskeleton of kidney podocytes is a direct target of the antiproteinuric effect of cyclosporine A. Nat Med. 2008; 14: 931-8
|
|
|
|
|
|
19) Xing CY, Saleem MA, Coward RJ. Direct effects of dexamethasone on human podocytes. Kidney Int. 2006; 70: 1038-45
|
|
|
|
|
|
20) Nakajo A, Khoshnoodi J, Takenaka H, et al. Mizoribine corrects defective nephrin biogenesis by restoring intracellular energy balance. J Am Soc Nephrol. 2007; 18: 2554-64
|
|
|
|
|
|
21) D'Agati VD, Fogo AB, Bruijn JA, et al. Pathologic classification of focal segmental glomerulosclerosis: a working proposal. Am J Kidney Dis. 2004; 43: 368-82
|
|
|
|
|
|
22) Yoshimoto K, Yokoyama H, Wada T, et al. Pathologic findings of initial biopsies reflect the outcomes of membranous nephropathy. Kidney Int. 2004; 65: 148-53
|
|
|
|
|
|
23) Cattran DC, Alexopoulos E, Heering P, et al. Cyclosporin in idiopathic glomerular disease associated with the nephrotic syndrome: workshop recommendations. Kidney Int. 2007; 72: 1429-47
|
|
|
|
|